cancer that has spread outside the colon and rectum) and in the United States, in combination with LUMAKRAS, for the treatment of adult patients with KRAS G12C-mutated mCRC, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. RAS status is determined by an FDA-approved test.
TEZSPIRE
Together with our collaboration partner, we market TEZSPIRE in many countries around the world. TEZSPIRE is currently approved for the treatment of severe asthma in the United States, Europe, Japan and more than 50 countries across the globe. TEZSPIRE is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants and other environmental insults.
Other Marketed Products
We also market a number of other products in various markets worldwide, including but not limited to AMJEVITA/AMGEVITA, MVASI, Neulasta, RAVICTI, UPLIZNA, Parsabiv, LUMAKRAS/LUMYKRAS, Aimovig, TAVNEOS, PROCYSBI, EPOGEN and IMDELLTRA.
Patents
The following table lists our outstanding material patents for the indicated product by territory, general subject matter and latest expiry date. Certain of the European patents are subjects of supplemental protection certificates that provide additional protection for the products in certain European countries beyond the dates listed in the table. See footnotes to the patent table below.
One or more patents with the same or earlier expiry dates may fall under the same general subject matter and are not listed separately.
5
(1)
A European patent with this subject matter may also be entitled to supplemental protection in one or more countries in Europe, and the length of any such extension will vary by country. For example, supplementary protection certificates have been issued related to the indicated products for patents in at least the following countries:
6
•
denosumab — France, Germany, Italy, Spain and the United Kingdom, expiring in November 2025
•
evolocumab — France, Italy, Spain and the United Kingdom, expiring in 2031
•
romosozumab — France, Germany, Italy, Spain and the United Kingdom, expiring in 2031
•
carfilzomib — France, Germany, Italy, Spain and the United Kingdom, expiring in 2030
•
blinatumomab — France, Germany, Italy, Spain and the United Kingdom, expiring in 2029
•
tezepelumab — France, Italy and Spain, expiring in 2033
•
inebilizumab — France, Italy and Spain, expiring in 2032
•
etelcalcetide — France, Germany, Italy, Spain and the United Kingdom, expiring in 2031
•
erenumab — France, Germany, Italy, Spain and the United Kingdom, expiring in 2033
•
avacopan — France, Italy, Spain and the United Kingdom, expiring in 2034
(2)
Regulatory data exclusivity for apremilast in Europe expires in 2026.
(3)
Pediatric exclusivity granted to 8/16/2028 for a patent with this subject matter.
(4)
We have biologic exclusivity in the United States covering teprotumumab-trbw that will expire in